Stock Price Forecast

Feb. 7, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Alkermes plc chart...

About the Company

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

CEO

Richard F. Pops

Exchange

NASDAQ

Website

www.alkermes.com

$1B

Total Revenue

2K

Employees

$4B

Market Capitalization

-18.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALKS News

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 45% Undervaluation?

5d ago, source:

How far off is Alkermes plc ( NASDAQ:ALKS ) from its intrinsic value? Using the most recent financial data, we'll ...

Alkermes PLC

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Client Profile: Alkermes Plc

16d ago, source: OpenSecrets.org

A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...

First Week of March 17th Options Trading For Alkermes (ALKS)

15d ago, source: Nasdaq

Investors in Alkermes plc (Symbol: ALKS) saw new options become available this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALKS ...

ALKS.OQ - Alkermes Plc | Stock Price & Latest News | Reuters

1mon ago, source: Reuters

Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed ...

Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference

1mon ago, source: Benzinga.com

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary ...

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

21d ago, source: Benzinga.com

DUBLIN, Jan. 17, 2023 /PRNewswire/ -- Alkermes plc ALKS today announced that nemvaleukin alfa (nemvaleukin), the company's investigational, novel engineered interleukin-2 (IL-2) variant ...

AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

19h ago, source: Zacks.com on MSN

AstraZeneca AZN will report fourth-quarter and full-year 2022 results on Feb 9. In the last reported quarter, the company ...

Amarin Mails Letter To Shareholders Highlighting Sarissa's Myths Vs. The Facts

1d ago, source:

Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the“Company”) today announced that it has mailed a letter to shareholders addressing the false and misleading statements made by Sarissa Capital ...

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 45% Undervaluation?

4d ago, source: Yahoo

How far off is Alkermes plc (NASDAQ:ALKS) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash ...

Alkermes (ALKS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

26d ago, source: Seeking Alpha

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...